Clinical data | |
---|---|
Trade names | Lotemax |
Other names | 11β,17α,Dihydroxy-21-oxa-21-chloromethylpregna-1,4-diene-3,20-dione 17α-ethylcarbonate |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Eye drops |
Drug class | Corticosteroid; glucocorticoid |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | None |
Protein binding | 95% |
Metabolism | Ester hydrolysis |
Metabolites | Δ1-cortienic acid and its etabonate |
Onset of action | ≤2 hrs (allergic conjunctivitis) |
Elimination half-life | 2.8 hrs |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.167.120 |
Chemical and physical data | |
Formula | C24H31ClO7 |
Molar mass | 466.96 g·mol−1 |
3D model (JSmol) | |
Melting point | 220.5 to 223.5 °C (428.9 to 434.3 °F) |
Solubility in water | 0.0005 mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Loteprednol (synthesized as the ester loteprednol etabonate) is a topical corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax[2] and Loterex.
It was patented in 1980 and approved for medical use in 1998.[3] It is available as a generic medication.[4]
AC
was invoked but never defined (see the help page).